Joan Merrill

Dr. Merrill is well known for precedent setting in her Biomarkers of Lupus Disease (BOLD) study, which revealed that decreasing background medications is essential to identifying efficacy of new agents. She took part in a ground-breaking study assessing anifrolumab in SLE. She received her medical training at Cornell University Medical College, New York, followed by an internship and residency at St. Luke’s/Roosevelt Hospital Center, a fellowship in rheumatology at NYU Medical Center, and a basic research fellowship at Columbia University.